T-cell acute lymphoblastic leukemia pediatric · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine N/A - intrathecal component | — | R 11 652 | 71d | — | — | — | — | — |
Etoposide and TBI, then allo HSCT Variant #03 | — | R 6 278 | — | — | — | — | — | — |
Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine N/A - intrathecal component Partial | — | R 5 721 | 71d | — | — | — | — | — |
Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone Variant #01 | — | R 3 206 | 42d | — | — | — | — | — |
Doxorubicin, L-asparaginase, Mercaptopurine, Methotrexate, Vincristine, Prednisone Partial | — | — | — | — | — | — | — | — |
L-asparaginase monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
Doxorubicin, L-asparaginase, Mercaptopurine, Vincristine, Prednisone Partial | — | — | — | — | — | — | — | — |
7 of 7 regimens shown